尼日利亚北部和南部两个州接受抗逆转录病毒疗法的成年人的艾滋病毒高血压治疗结果:横断面设计方法。

IF 3.8 Q2 INFECTIOUS DISEASES
Therapeutic Advances in Infectious Disease Pub Date : 2024-11-04 eCollection Date: 2024-01-01 DOI:10.1177/20499361241293704
Oluseye Ayodele Ajayi, Deborah Babatunde, Oluwaseun Kikelomo Ajayi, Temitope Olumuyiwa Ojo, Prosper Okonkwo
{"title":"尼日利亚北部和南部两个州接受抗逆转录病毒疗法的成年人的艾滋病毒高血压治疗结果:横断面设计方法。","authors":"Oluseye Ayodele Ajayi, Deborah Babatunde, Oluwaseun Kikelomo Ajayi, Temitope Olumuyiwa Ojo, Prosper Okonkwo","doi":"10.1177/20499361241293704","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The combined effect of the aging human immunodeficiency virus (HIV) population, HIV's natural progression, and HIV drugs have great implications for comorbidity burden and hypertension control among people living with HIV (PLHIV).</p><p><strong>Objectives: </strong>This study assessed hypertension burden, treatment outcomes, and treatment outcome predictors among PLHIV in Nigeria.</p><p><strong>Design: </strong>Cross-sectional design.</p><p><strong>Methods: </strong>A cross-sectional study of 2613 adult PLHIV who initiated antiretroviral therapy (ART) between 2004 and 2020 in two HIV clinics in Northern and Southern Nigeria. Study outcomes were: (1) controlled blood pressure defined as two consecutive blood pressure (BP) measurements of <140/90 mmHg (Joint National Committee guideline (JNC) 7) on the interview day in previously diagnosed hypertensive participants; and (2) HIV viral suppression defined as recent viral load count of <1000 copies/ml in a hypertensive participant. Data were analyzed using Statistical Package of Social Sciences IBM version 23. Univariate and multivariate logistic regression was done to ascertain factors associated with the study outcomes at <i>p</i> < 0.05.</p><p><strong>Result: </strong>The mean age of respondents at the point of the study was 45.3 ± 9.8 years. Most of the participants were female, 1940 (74.2%), on a dolutegravir-based therapy, 2433 (93.2%). About 452 (17.3%) of the participants had clinically diagnosed hypertension. Of those diagnosed hypertensives, 443 (98.0%) were on antihypertensive drugs. About 407 (90.0%) and 229 (51.7%) of the hypertensive PLHIV had HIV viral suppression and controlled hypertension respectively. Factors associated with controlled hypertension were age at ART initiation (adjusted odds ratio (AOR): 0.96, 95% CI: 0.94-0.98), use of thiazide only antihypertensive (AOR: 1.91, 95% CI: 1.73-3.24, Ref: calcium channel blocker only) and thiazide-calcium channel blocker combination (AOR: 2.19, 95% CI: 1.05-4.58). No hypertension comorbidity-related factors were found to be associated with HIV viral suppression.</p><p><strong>Conclusion: </strong>There is suboptimal hypertension control among hypertensive PLHIV especially those on non-thiazide-based antihypertensive drugs. Close monitoring should be given to hypertension management in PLHIV.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":null,"pages":null},"PeriodicalIF":3.8000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11536368/pdf/","citationCount":"0","resultStr":"{\"title\":\"HIV-hypertension treatment outcomes among adults on antiretroviral therapy in two states in Northern and Southern Nigeria: a cross-sectional design approach.\",\"authors\":\"Oluseye Ayodele Ajayi, Deborah Babatunde, Oluwaseun Kikelomo Ajayi, Temitope Olumuyiwa Ojo, Prosper Okonkwo\",\"doi\":\"10.1177/20499361241293704\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The combined effect of the aging human immunodeficiency virus (HIV) population, HIV's natural progression, and HIV drugs have great implications for comorbidity burden and hypertension control among people living with HIV (PLHIV).</p><p><strong>Objectives: </strong>This study assessed hypertension burden, treatment outcomes, and treatment outcome predictors among PLHIV in Nigeria.</p><p><strong>Design: </strong>Cross-sectional design.</p><p><strong>Methods: </strong>A cross-sectional study of 2613 adult PLHIV who initiated antiretroviral therapy (ART) between 2004 and 2020 in two HIV clinics in Northern and Southern Nigeria. Study outcomes were: (1) controlled blood pressure defined as two consecutive blood pressure (BP) measurements of <140/90 mmHg (Joint National Committee guideline (JNC) 7) on the interview day in previously diagnosed hypertensive participants; and (2) HIV viral suppression defined as recent viral load count of <1000 copies/ml in a hypertensive participant. Data were analyzed using Statistical Package of Social Sciences IBM version 23. Univariate and multivariate logistic regression was done to ascertain factors associated with the study outcomes at <i>p</i> < 0.05.</p><p><strong>Result: </strong>The mean age of respondents at the point of the study was 45.3 ± 9.8 years. Most of the participants were female, 1940 (74.2%), on a dolutegravir-based therapy, 2433 (93.2%). About 452 (17.3%) of the participants had clinically diagnosed hypertension. Of those diagnosed hypertensives, 443 (98.0%) were on antihypertensive drugs. About 407 (90.0%) and 229 (51.7%) of the hypertensive PLHIV had HIV viral suppression and controlled hypertension respectively. Factors associated with controlled hypertension were age at ART initiation (adjusted odds ratio (AOR): 0.96, 95% CI: 0.94-0.98), use of thiazide only antihypertensive (AOR: 1.91, 95% CI: 1.73-3.24, Ref: calcium channel blocker only) and thiazide-calcium channel blocker combination (AOR: 2.19, 95% CI: 1.05-4.58). No hypertension comorbidity-related factors were found to be associated with HIV viral suppression.</p><p><strong>Conclusion: </strong>There is suboptimal hypertension control among hypertensive PLHIV especially those on non-thiazide-based antihypertensive drugs. Close monitoring should be given to hypertension management in PLHIV.</p>\",\"PeriodicalId\":46154,\"journal\":{\"name\":\"Therapeutic Advances in Infectious Disease\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2024-11-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11536368/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Infectious Disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/20499361241293704\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Infectious Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20499361241293704","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

背景:人类免疫缺陷病毒(HIV)人群的老龄化、HIV 的自然发展以及 HIV 药物的综合影响对 HIV 感染者(PLHIV)的合并症负担和高血压控制产生了重大影响:本研究评估了尼日利亚艾滋病毒感染者的高血压负担、治疗效果和治疗效果预测因素:设计:横断面设计:方法:对尼日利亚北部和南部两家 HIV 诊所 2004 年至 2020 年期间开始接受抗逆转录病毒疗法(ART)的 2613 名成年 PLHIV 进行横断面研究。研究结果如下(1) 血压得到控制,即连续两次血压测量结果均为 p:研究时受访者的平均年龄为 45.3 ± 9.8 岁。大多数参与者为女性,1940 人(74.2%),2433 人(93.2%)正在接受基于多罗替拉韦的治疗。约有 452 人(17.3%)经临床诊断患有高血压。在这些确诊的高血压患者中,有 443 人(98.0%)正在服用降压药。约 407 名(90.0%)和 229 名(51.7%)高血压 PLHIV 感染者的 HIV 病毒得到抑制,高血压得到控制。与高血压得到控制相关的因素有:开始接受抗逆转录病毒疗法时的年龄(调整后的几率比(AOR):0.96,95% CI:0.94-0.98)、仅使用噻嗪类降压药(AOR:1.91,95% CI:1.73-3.24,参考:仅使用钙通道阻滞剂)和噻嗪-钙通道阻滞剂联合用药(AOR:2.19,95% CI:1.05-4.58)。没有发现高血压合并症相关因素与艾滋病病毒抑制有关:结论:高血压 PLHIV 的高血压控制不理想,尤其是那些服用非噻嗪类降压药的 PLHIV。应密切监测 PLHIV 的高血压控制情况。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
HIV-hypertension treatment outcomes among adults on antiretroviral therapy in two states in Northern and Southern Nigeria: a cross-sectional design approach.

Background: The combined effect of the aging human immunodeficiency virus (HIV) population, HIV's natural progression, and HIV drugs have great implications for comorbidity burden and hypertension control among people living with HIV (PLHIV).

Objectives: This study assessed hypertension burden, treatment outcomes, and treatment outcome predictors among PLHIV in Nigeria.

Design: Cross-sectional design.

Methods: A cross-sectional study of 2613 adult PLHIV who initiated antiretroviral therapy (ART) between 2004 and 2020 in two HIV clinics in Northern and Southern Nigeria. Study outcomes were: (1) controlled blood pressure defined as two consecutive blood pressure (BP) measurements of <140/90 mmHg (Joint National Committee guideline (JNC) 7) on the interview day in previously diagnosed hypertensive participants; and (2) HIV viral suppression defined as recent viral load count of <1000 copies/ml in a hypertensive participant. Data were analyzed using Statistical Package of Social Sciences IBM version 23. Univariate and multivariate logistic regression was done to ascertain factors associated with the study outcomes at p < 0.05.

Result: The mean age of respondents at the point of the study was 45.3 ± 9.8 years. Most of the participants were female, 1940 (74.2%), on a dolutegravir-based therapy, 2433 (93.2%). About 452 (17.3%) of the participants had clinically diagnosed hypertension. Of those diagnosed hypertensives, 443 (98.0%) were on antihypertensive drugs. About 407 (90.0%) and 229 (51.7%) of the hypertensive PLHIV had HIV viral suppression and controlled hypertension respectively. Factors associated with controlled hypertension were age at ART initiation (adjusted odds ratio (AOR): 0.96, 95% CI: 0.94-0.98), use of thiazide only antihypertensive (AOR: 1.91, 95% CI: 1.73-3.24, Ref: calcium channel blocker only) and thiazide-calcium channel blocker combination (AOR: 2.19, 95% CI: 1.05-4.58). No hypertension comorbidity-related factors were found to be associated with HIV viral suppression.

Conclusion: There is suboptimal hypertension control among hypertensive PLHIV especially those on non-thiazide-based antihypertensive drugs. Close monitoring should be given to hypertension management in PLHIV.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.30
自引率
8.80%
发文量
64
审稿时长
9 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信